[HTML][HTML] Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B. 1.617 variants
New England Journal of Medicine, 2021•Mass Medical Soc
Neutralizing Activity against SARS-CoV-2 Variants Among samples obtained from persons
who had received the mRNA-1273 or BNT162b2 vaccines, neutralizing antibody titers
against the B. 1.617. 1 variant were 6.8 times lower than those against the WA1/2020
variant, and titers against the B. 1.617. 2 variant were 2.9 times lower than those against
WA1/2020.
who had received the mRNA-1273 or BNT162b2 vaccines, neutralizing antibody titers
against the B. 1.617. 1 variant were 6.8 times lower than those against the WA1/2020
variant, and titers against the B. 1.617. 2 variant were 2.9 times lower than those against
WA1/2020.
Neutralizing Activity against SARS-CoV-2 Variants
Among samples obtained from persons who had received the mRNA-1273 or BNT162b2 vaccines, neutralizing antibody titers against the B.1.617.1 variant were 6.8 times lower than those against the WA1/2020 variant, and titers against the B.1.617.2 variant were 2.9 times lower than those against WA1/2020.
The New England Journal Of Medicine